Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival

Lu,Jing; Zhang,Guohong; Cheng,Yabin; Tang,Yun; Dong,Ziming; McElwee,Kevin J.; Li,Gang

doi:10.3892/or.2014.3534

Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival

Authors:
- Jing Lu
- Guohong Zhang
- Yabin Cheng
- Yun Tang
- Ziming Dong
- Kevin J. McElwee
- Gang Li
View Affiliations

Affiliations: Department of Dermatology and Skin Science, Research Pavilion, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC V5Z 1L8, Canada, Department of Pathophysiology, Basic Medical College, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
Published online on: October 8, 2014 https://doi.org/10.3892/or.2014.3534
Pages: 2571-2579

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SRY-box containing gene 17 (Sox17), a transcription factor, is considered as an antagonist to canonical Wnt/β‑catenin signaling in several types of malignant tumors. As the influence of Sox17 in the pathogenesis of human melanoma is still unknown, the investigation of Sox17 expression in melanoma is warranted and its prognostic value is of great interest. In the present study, Sox17 expression was examined in 525 cases of melanocytic lesions (33 common acquired nevi, 59 dysplastic nevi, 291 primary melanomas and 142 metastatic melanomas) at different stages by tissue microarray. The correlation of Sox17 expression with melanoma progression and its prognostic value in melanoma patients were examined. We also analyzed the correlation between Sox17 and cyclin-dependent kinase inhibitor p27 expression in 374 melanoma samples. The results showed that Sox17 expression was significantly decreased in primary and metastatic melanoma compared to common acquired nevi and dysplastic nevi (P=2.4x10-17). Furthermore, Sox17 expression was inversely correlated with American Joint Committee on Cancer stage (P=4.6x10-15), thickness (P=0.00004) and ulceration (P=0.03). Notably, reduced Sox17 expression was correlated with a poorer overall and disease-specific 5- and 10-year survival of the patients. Multivariate Cox regression analyses indicated that Sox17 is an independent prognostic marker for melanoma patients. Moreover, we found a significant positive correlation between Sox17 and p27 expression in melanoma biopsies; their concomitant expression was closely correlated with the survival of melanoma patients. Taken together, decreased Sox17 expression is correlated with melanoma progression, an unfavorable survival of melanoma patients and is an independent molecular prognostic factor for melanoma.

View Figures

View References

1	Miller AJ and Mihm MC Jr: Melanoma. N Engl J Med. 355:51–65. 2006. View Article : Google Scholar
2	Trinh VA: Current management of metastatic melanoma. Am J Health Syst Pharm. 65:S3–S8. 2008. View Article : Google Scholar : PubMed/NCBI
3	Geller AC, Swetter SM, Brooks K, Demierre MF and Yaroch AL: Screening, early detection, and trends for melanoma: current status (2000–2006) and future directions. J Am Acad Dermatol. 57:555–576. 2007.PubMed/NCBI
4	Geller AC, Swetter SM, Oliveria S, Dusza S and Halpern AC: Reducing mortality in individuals at high risk for advanced melanoma through education and screening. J Am Acad Dermatol. 65:S87–S94. 2011. View Article : Google Scholar : PubMed/NCBI
5	Turner RM, Bell KJ, Morton RL, et al: Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol. 29:4641–4646. 2011. View Article : Google Scholar : PubMed/NCBI
6	Gubbay J, Collignon J, Koopman P, et al: A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature. 346:245–250. 1990. View Article : Google Scholar : PubMed/NCBI
7	Wegner M: From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 27:1409–1420. 1999. View Article : Google Scholar : PubMed/NCBI
8	Burtscher I, Barkey W, Schwarzfischer M, Theis FJ and Lickert H: The Sox17-mCherry fusion mouse line allows visualization of endoderm and vascular endothelial development. Genesis. 50:496–505. 2012. View Article : Google Scholar : PubMed/NCBI
9	Niakan KK, Ji H, Maehr R, et al: Sox17 promotes differentiation in mouse embryonic stem cells by directly regulating extraembryonic gene expression and indirectly antagonizing self-renewal. Genes Dev. 24:312–326. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chen HL, Chew LJ, Packer RJ and Gallo V: Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation. Cancer Lett. 335:361–371. 2013. View Article : Google Scholar : PubMed/NCBI
11	Jia Y, Yang Y, Liu S, Herman JG, Lu F and Guo M: SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma. Epigenetics. 5:743–749. 2010.
12	Ye YW, Wu JH, Wang CM, et al: Sox17 regulates proliferation and cell cycle during gastric cancer progression. Cancer Lett. 307:124–131. 2011. View Article : Google Scholar : PubMed/NCBI
13	Li D, Beisswenger C, Herr C, et al: Myeloid cell RelA/p65 promotes lung cancer proliferation through Wnt/β-catenin signaling in murine and human tumor cells. Oncogene. 33:1239–1248. 2013.PubMed/NCBI
14	Yang L, Chen Y, Cui T, et al: Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer. Carcinogenesis. 33:1863–1870. 2012.PubMed/NCBI
15	Zeitlin BD, Ellis LM and Nor JE: Inhibition of vascular endothelial growth factor receptor-1/Wnt/{beta}-catenin crosstalk leads to tumor cell death. Clin Cancer Res. 15:7453–7455. 2009. View Article : Google Scholar : PubMed/NCBI
16	Fodde R and Brabletz T: Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 19:150–158. 2007.
17	Fu DY, Wang ZM, Li C, et al: Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat. 119:601–612. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhang W, Glockner SC, Guo M, et al: Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 68:2764–2772. 2008. View Article : Google Scholar : PubMed/NCBI
19	Du YC, Oshima H, Oguma K, et al: Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology. 137:1346–1357. 2009. View Article : Google Scholar : PubMed/NCBI
20	Chu IM, Hengst L and Slingerland JM: The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008. View Article : Google Scholar : PubMed/NCBI
21	Wander SA, Zhao D and Slingerland JM: p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res. 17:12–18. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chen G, Cheng Y, Zhang Z, Martinka M and Li G: Prognostic significance of cytoplasmic p27 expression in human melanoma. Cancer Epidemiol Biomarkers Prev. 20:2212–2221. 2011. View Article : Google Scholar : PubMed/NCBI
23	Tao GZ, Lehwald N, Jang KY, et al: Wnt/β-catenin signaling protects mouse liver against oxidative stress-induced apoptosis through the inhibition of forkhead transcription factor FoxO3. J Biol Chem. 288:17214–17224. 2013.
24	Dai DL, Martinka M and Li G: Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 23:1473–1482. 2005. View Article : Google Scholar : PubMed/NCBI
25	Lin H, Wong RP, Martinka M and Li G: Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin Cancer Res. 15:6404–6411. 2009. View Article : Google Scholar : PubMed/NCBI
26	Yang H, Lee S, Kim K, et al: Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice. J Clin Invest. 123:418–431. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yin D, Jia Y, Yu Y, et al: SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. Discov Med. 14:33–40. 2012.PubMed/NCBI
28	Jia Y, Yang Y, Zhan Q, et al: Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer. J Mol Diagn. 14:577–585. 2012. View Article : Google Scholar : PubMed/NCBI
29	Oishi Y, Watanabe Y, Yoshida Y, et al: Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour Biol. 33:383–393. 2012. View Article : Google Scholar : PubMed/NCBI
30	Tarhini AA and Agarwala SS: Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther. 19:19–25. 2006. View Article : Google Scholar : PubMed/NCBI
31	Sinner D, Kordich JJ, Spence JR, et al: Sox17 and Sox4 differentially regulate β-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 27:7802–7815. 2007.PubMed/NCBI
32	Sohn J, Natale J, Chew LJ, et al: Identification of Sox17 as a transcription factor that regulates oligodendrocyte development. J Neurosci. 26:9722–9735. 2006. View Article : Google Scholar : PubMed/NCBI